- Alzheimer’s drugs market to grow in next 5 years
21 Jul 2017
The global Alzheimer’s drugs market to grow at a CAGR of 1.90% during the period 2017-2021, according to ResearchandMarkets, with Key vendors being Allergan, Eisai Pharmaceuticals, Johnson & Johnson, and Novartis, with other other prominent vendors Amgen and Pfizer.
- Pharming Group in repayment of bridge finance on unchanged terms
21 Jul 2017
Pharming Group N.V. has completed the replacement of its recently announced $100 million bridge finance with OrbiMed Advisors with a $100 million permanent facility agreement with OrbiMed Advisors.
- EC approves marketing to Vitor Pharma’s Veltassa for hyperkalaemia
21 Jul 2017
The European Commission has approved patriometer to be marketed as Veltassa in the 28 EU countries for treating hyperkalaemia in adult patients.
- SillaJen, Lee’s Pharmaceutical cleared for third phase testing cancer treatment Pexa-Vec
21 Jul 2017
SillaJen and Lee’s Pharmaceutical Holdings have said that they’ve gotten the approval from the China Food and Drug Administration (CFDA) to get a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec, the PHOCUS study.
- GSK plans to cut 320 jobs
20 Jul 2017
GSK on Wednesday set out several announcements made by the company to improve the efficiency and competitiveness of its manufacturing network, including investments for respiratory and HIV medicines manufacturing in the UK and strategic reviews. This includes the sale of several products and a proposal to close a UK manufacturing site.
- Ceylad kicks off SHRINK trial targeting metastatic colorectal patients
20 Jul 2017
Celyad has kicked off the SHRINK trial, a third clinical trial with its lead product candidate CYAD-01 (CAR-T NKG2D), targeting metastatic colorectal patients, the company said Thursday.
- Ablynx, Sanofi in multimillion euros deal for treating inflammatory disease
20 Jul 2017
Ablynx and Sanofi have made a deal for research collaboration and global exclusive licensing agreement related to Nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases.
- Calyxt in pricing of $56.0 million initial public offering
20 Jul 2017
Cellectis S.A. and Calyxt, Inc. announced on Thursday the pricing of Calyxt’s initial public offering of 7,000,000 shares of its common stock at the initial public offering price of $8.00 per share.
- FDA accepts new IND to expand in U.S. IFNalpha kinoid clinical development program in dermatomyositis
19 Jul 2017
The U.S. Food and Drug Administration (FDA) has cleared Neovacs’s Investigational New Drug (IND) application for IFNalpha Kinoid in the treatment of dermatomyositis, which allows the Company to initiate in the US its Phase IIa clinical trial already on-going in European countries.
- South Korea continues to be a global pioneer in innovation
19 Jul 2017
CPhI Korea returns to Seoul COEX Convention and Exhibition Centre for its fourth edition from 22nd-24th August 2017. The show will co-locate with ICSE, P-MEC, BioPh and Health Ingredients Korea. Reflecting the global interest in the South Korean pharma market, CPhI Korea 2017 will see a 13% rise in the number of exhibitors, in addition to a more than doubling of overseas buyers since 2015.
My Pharmaceutical
NIH: Social interaction affects cancer patients’ response to treatment
How well cancer patients fared after chemotherapy was affected by their social interaction with other patients during treatment, according to a new study by researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, and the University of Oxford in the United Kingdom.
- Map of malaria funding in Africa uneven despite death risks – study
About a quarter of countries in sub-Saharan Africa receive little funding for research into malaria despite having high death rates, according to a study on Thursday that highlighted the unequal spread of resources to tackle the disease.
- Strength training for longer and better living
Regular physical activity promotes general good health, reduces the risk of developing many diseases, and helps you live a longer and healthier life. For many of us, “exercise” means walking, jogging, treadmill work, or other activities that get the heart pumping.
- Mitra, Fuji Pharma ink women’s health product deal in Japan
An exclusive License and Supply Agreement (LSA) has been signed between Fuji Pharma, the leader in women’s health in Japan, and Mithra, a Euronext -listed company specialized in women’s health, for the commercialization of Donesta in Japan and ASEAN territories.
